Solventum stock has quietly put up a 13.1% return over the past year, and the valuation checks now suggest the shares lean toward the cheaper side rather than looking stretched after that move.

• Over the past 12 months Solventum has returned 13.1%, which is enough to make the current pricing worth a closer look rather than assuming it is either a bargain or overheated.
• The planned separation of the Health Information Systems software business may support a sharper focus on MedTech returns. However, execution risk around carving out that unit and reinvesting in the core operations can still affect what investors are willing to pay.
• On Simply Wall St's broader valuation checks, Solventum scores 5 out of 6, which suggests the stock currently screens as relatively cheap across most of the main measures used.

For investors, the debate is whether the current share price already reflects the benefits of the portfolio shift or if Solventum still offers a margin of safety on valuation.

Does Solventum Look Undervalued on Earnings?

The P/E multiple suits Solventum because you are comparing what you pay today with the earnings that already exist. Right now Solventum trades at about 9.9x earnings, which is far below the Medical Equipment industry average of 26.1x and the peer group average of 67.1x. That gap means the market is paying a much lower price for each dollar of Solventum earnings than for many other MedTech stocks.

The fair P/E ratio for Solventum is estimated at 21.0x. This estimate already tries to factor in its industry, margins, scale and risk profile. Against that yardstick, the current 9.9x level is materially lower, which indicates a discount rather than a full price. Despite the planned separation of the Health Information Systems software business adding interest around the story, the P/E still sits well below both the tailored fair ratio and sector benchmarks.

On the P/E multiple, Solventum stock currently appears undervalued.

The Solventum Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Solventum valuation puzzle leaves off by explaining which assumptions about Solventum's future earnings, growth and margins would need to hold for the stock to be worth significantly more or less than today's price. Each narrative presents Solventum's fair value as a thesis about the business that you can track over time, rather than a single static number. These narratives appear on Simply Wall St's Community page.

The community is split on Solventum, with one side focused on the upside from the portfolio reshaping and the other on the execution risks around it.

Bull case: 11% undervalued

"Recent commercial restructuring and specialized sales teams are delivering above-expectation growth, especially in core areas like MedSurg and Dental, indicating that further market penetration and differentiated brand leverage could drive ongoing volume-based revenue increases and support margin expansion..."

Bear case: 35% overvalued

"The multiyear Transform for the Future restructuring and ERP conversions risk execution missteps that could disrupt manufacturing, distribution and customer service..."

Do you think there's more to the story for Solventum? Head over to our Community to see what others are saying!

The Bottom Line

Solventum screens as undervalued on market multiples, with the current P/E sitting well below both its tailored fair ratio and sector averages. That points to a discount that only makes sense if investors stay cautious about execution around the portfolio reshaping and broader restructuring programs. The key question from here is whether Solventum can deliver stable earnings and margin progress through these changes, so that the current discount closes rather than turning into a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.